Figure 1 | Scientific Reports

Figure 1

From: Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer

Figure 1

Overview of the methods for sample collection and sequencing. (A) Tumor samples from biopsy were obtained at baseline (T0). Blood samples were obtained at baseline (T0), Cycle 1 Day 3 (T1), at time of surgery (T2), during follow-up (T3- every 3–6 month intervals for 5 years), and during relapse (T4). (B) Baseline tumor samples were subjected to whole exome sequencing (WES) and variants were identified to build a custom micro-panel. All blood samples (T0–T4) were assessed using the amplicon based custom micro-panel. C. Sequencing was subjected to unique molecular identifier (UMI) based error correction. Variant allele fractions (VAFs) were ascertained for baseline biopsies and ctDNA blood samples at all timepoints.

Back to article page